美国眼科处方药支出与自付费用趋势分析(2007–2016)
该研究基于2007至2016年美国医疗支出面板调查(MEPS)中18岁以上参与者数据,采用回顾性纵向队列设计,估计眼科处方药总支出与自付费用的年度趋势。人均支出从338.72美元增至499.42美元(P<0.001),人均自付从133.48美元降至96.67美元(P<0.001)。2015–2016年干眼(29.5%)和青光眼(42.7%)药物占全部眼科药物支出的72.2%。
要点
- 眼科处方药全国总支出十年间显著增加,自付支出下降。
- 2015–2016年干眼与青光眼药物合计占眼科药物支出的72.2%。
- 年龄>65岁、无保险和视力损害者自付支出更高(P<0.001)。
核心结论
- 美国眼科处方药总支出在2007–2016年间显著增加,而自付支出下降。
- 覆盖增加、共付援助及高价品牌药使用可能促成了上述趋势。
研究设计与样本
- 回顾性纵向队列研究,使用2007–2016年MEPS中18岁以上参与者数据。
- 将数据合并为两年周期,采用加权线性回归估计趋势,成本经GDP价格指数调整至2016年美元。
主要发现
- 人均支出从338.72美元增至499.42美元(P<0.001),人均自付从133.48美元降至96.67美元(P<0.001)。
- 2015–2016年干眼药物占29.5%、青光眼药物占42.7%,合计占72.2%的眼科药物支出。
- 年龄>65岁、无保险和视力损害者自付支出显著更高(P<0.001)。
关键数值与推荐
- 2007–2016年共9989名MEPS参与者(4.2%)报告使用眼科处方药。
- 人均支出338.72→499.42美元(P<0.001);人均自付133.48→96.67美元(P<0.001)。
- 2015–2016年干眼占29.5%、青光眼占42.7%,合计72.2%。
临床怎么用
- 临床医生应关注整体药费上升可能增加患者间接成本,抵消自付下降的获益。
- 对高龄、无保险及视力损害患者,处方时需特别考虑其自付负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To estimate temporal trends in total and out-of-pocket (OOP) expenditures for ophthalmic prescription medications among adults in the United States. DESIGN: Retrospective, longitudinal cohort study. PARTICIPANTS: Participants in the 2007 through 2016 Medical Expenditure Panel Survey (MEPS) 18 years of age or older. The MEPS is a nationally representative survey of the noninstitutionalized, civilian United States population. METHODS: We estimated trends in national and per capita annual ophthalmic prescription expenditures by pooling data into 2-year cycles and using weighted linear regressions. We also identified characteristics associated with greater total or OOP expenditures with multivariate weighted linear regression. Costs were adjusted to 2016 United States dollars using the gross domestic product price index. MAIN OUTCOME MEASURES: Trends in total and OOP annual expenditures for ophthalmic medications from 2007 through 2016 as well as factors associated with greater expenditures. RESULTS: From 2007 through 2016, 9989 MEPS participants (4.2%) reported ophthalmic medication prescription use. Annual ophthalmic medication use increased from 10.0 to 12.2 million individuals from 2007 and 2008 through 2015 and 2016. In this same period, national expenditures for ophthalmic medications increased from $3.39 billion to $6.08 billion and OOP expenditures decreased from $1.34 to $1.18 billion. Per capita expenditure increased from $338.72 to $499.42 (P < 0.001), and per capita OOP expenditure decreased from $133.48 to $96.67 (P < 0.001) from 2007 and 2008 through 2015 and 2016, respectively. From 2015 through 2016, dry eye (29.5%) and glaucoma (42.7%) medications accounted for 72.2% of all ophthalmic medication expenditures. Patients who were older than 65 years (P < 0.001), uninsured (P < 0.001), and visually impaired (P < 0.001) were significantly more likely to have greater OOP spending on ophthalmic medications. CONCLUSIONS: Total ophthalmic medication expenditure in the United States increased significantly over the last decade, whereas OOP expenses decreased. Increases in coverage, copayment assistance, and use of expensive brand drugs may be contributing to these trends. Policy makers and physicians should be aware that rising overall drug expenditures ultimately may increase indirect costs to the patient and offset a decline in OOP prescription drug spending.
引用
- Chen EM, Kombo N, Teng CC, et al. Ophthalmic Medication Expenditures and Out-of-Pocket Spending: An Analysis of United States Prescriptions from 2007 through 2016. Ophthalmology. 2020. PMID: 32359935. doi:10.1016/j.ophtha.2020.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。